Myelodysplastic Syndromes

Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Web Exclusives
Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo.
Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes
Best Practices in Hematologic Malignancies – December 2019 Vol 10
Loading More Articles

Results 1 - 2 of 2

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512